Phillips Medisize Advances Embedded Sensing Ahead of INTERPHEX 2026

Phillips Medisize is advancing embedded sensing and custom engineering in bioprocessing systems, as it prepares to present its work at INTERPHEX 2026.

The company is focusing on integrating intelligence directly into single-use assemblies, turning them into “data-rich, decision-ready assets,” according to a company statement.

Rich Jones, PhD, Vice President of IVD and Life Sciences at Phillips Medisize, said the shift is driven by increasing complexity in drug development, where standard platform approaches are becoming less effective.

This includes cell and gene therapies and other advanced biologics that require tailored workflows rather than reliance on off-the-shelf components, based on INTERPHEX 2026 coverage.

Phillips Medisize Embeds Sensors Into Single-Use Systems

Phillips Medisize is working to move sensing capabilities from external devices into the bioprocessing flow path itself.

Jones said traditional systems rely on external sensors such as clamp-on flow meters and optical probes, which can introduce measurement limitations and contamination risks, according to INTERPHEX 2026 reporting.

The company’s approach integrates sensors directly into single-use components such as tubing and bags, enabling inline monitoring of parameters including pH, dissolved oxygen, and metabolite levels.

These embedded sensors can transmit data wirelessly using technologies such as near field communication and Bluetooth Low Energy, allowing real-time monitoring without breaching sterile boundaries.

Phillips Medisize is also targeting continuous integrity monitoring by embedding sensing elements at connection points. This allows systems to verify in real time that closed processes remain sealed, replacing discrete testing steps.

Jones said this shift creates a component-level data record of process conditions, including temperature history and mechanical stress, which can feed into electronic batch records and support real-time release workflows.

The company expects commercially validated embedded sensor systems to emerge in the next three to five years, with broader adoption over the following decade, based on the same report.

Fit-for-Purpose Engineering Replaces Standard Platforms

Phillips Medisize is positioning fit-for-purpose engineering as a response to the limits of standardized bioprocessing platforms.

Jones said many companies have relied on off-the-shelf components to accelerate development timelines, but these components often require process modifications across different molecules, reducing efficiency.

The company is applying rapid prototyping and iterative design to develop customized components that align with specific process requirements.

Phillips Medisize said this approach supports faster development cycles by reducing the need for downstream adjustments and improving manufacturability at scale.

The integration of embedded sensing extends this model by providing continuous data across the manufacturing lifecycle, enabling real-time monitoring and automated data capture.

INTERPHEX 2026 is expected to focus on these shifts, including modular manufacturing systems, digital integration, and supply chain resilience, as companies adapt to more complex drug pipelines.

Jones said cross-disciplinary collaboration between engineering, process science, quality, and regulatory teams will be required to implement these systems at scale.

Phillips Medisize is presenting its capabilities in this area at the event, positioning embedded sensing and customized system design as part of its broader bioprocessing strategy.